Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

被引：15
作者：
Luo, Shuang [1 ,2 ,3 ,4 ]
Jiang, Yu [5 ]
Zheng, Anfu [1 ,2 ,3 ]
Zhao, Yueshui [1 ,2 ,3 ]
Wu, Xu [1 ,2 ,3 ]
Li, Mingxing [1 ,2 ,3 ]
Du, Fukuan [1 ,2 ,3 ]
Chen, Yu [1 ,2 ,3 ]
Deng, Shuai [1 ,2 ,3 ]
Chen, Meijuan [1 ,2 ,3 ]
Li, Wanping [1 ,2 ,3 ]
Li, Xiaobing [1 ,2 ,3 ]
Gu, Li [1 ,2 ,3 ]
Sun, Yuhong [1 ,2 ,3 ]
Xiao, Zhangang [2 ,6 ]
Shen, Jing [1 ,2 ,3 ]
机构：
[1] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China
[2] Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China
[3] South Sichuan Inst Translat Med, Luzhou, Peoples R China
[4] Second Peoples Hosp Jiangyou, Dept Pharm, Mianyang, Peoples R China
[5] Peoples Hosp Wusheng, Dept Pharm, Guangan, Peoples R China
[6] Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China
来源：
FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷
基金：
中国国家自然科学基金;
关键词：
hypoxia-inducible factors; breast cancer; drug delivery systems; tumor microenvironment; angiogenesis; glycolysis; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELL; TUMOR ANGIOGENESIS; FACTOR-I; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA HIF-1-ALPHA; ANTIANGIOGENIC THERAPY; ANTICANCER ACTIVITY; AEROBIC GLYCOLYSIS; MASTER REGULATORS; PYRUVATE-KINASE;
D O I：
10.3389/fphar.2022.1064661
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.
引用
收藏
页数：20
相关论文
共 140 条
[41]   Hypoxia - A key regulatory factor in tumour growth [J].
Harris, AL .
NATURE REVIEWS CANCER, 2002, 2 (01) :38-47
[42]   Hypoxia-inducible factor as an angiogenic master switch [J].
Hashimoto, Takuya ;
Shibasaki, Futoshi .
FRONTIERS IN PEDIATRICS, 2015, 3
[43]   Hypoxia-inhibited miR-338-3p suppresses breast cancer progression by directly targeting ZEB2 [J].
He, Juanjuan ;
Wang, Jing ;
Li, Songchao ;
Li, Teng ;
Chen, Kunlun ;
Zhang, Shaojin .
CANCER SCIENCE, 2020, 111 (10) :3550-3563
[44]   Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects:: A phase I clinical trial [J].
Hortobagyi, GN ;
Ueno, NT ;
Xia, WY ;
Zhang, S ;
Wolf, JK ;
Putnam, JB ;
Weiden, PL ;
Willey, JS ;
Carey, M ;
Branham, DL ;
Payne, JY ;
Tucker, SD ;
Bartholomeusz, C ;
Kilbourn, RG ;
De Jager, RL ;
Sneige, N ;
Katz, RL ;
Anklesaria, P ;
Ibrahim, NK ;
Murray, JL ;
Theriault, RL ;
Valero, V ;
Gershenson, DM ;
Bevers, MW ;
Huang, L ;
Lopez-Berestein, G ;
Hung, MC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3422-3433
[45]   Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation [J].
Hu, CJ ;
Wang, LY ;
Chodosh, LA ;
Keith, B ;
Simon, MC .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (24) :9361-9374
[46]   Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? [J].
Huang, Yanqing ;
Lin, Daniel ;
Taniguchi, Cullen M. .
SCIENCE CHINA-LIFE SCIENCES, 2017, 60 (10) :1114-1124
[47]   The human hypoxia-inducible factor 1α gene:: HIF1A structure and evolutionary conservation [J].
Iyer, NV ;
Leung, SW ;
Semenza, GL .
GENOMICS, 1998, 52 (02) :159-165
[48]   Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors [J].
Jeong, Woondong ;
Park, Sook Ryun ;
Rapisarda, Annamaria ;
Fer, Nicole ;
Kinders, Robert J. ;
Chen, Alice ;
Melillo, Giovanni ;
Turkbey, Baris ;
Steinberg, Seth M. ;
Choyke, Peter ;
Doroshow, James H. ;
Kummar, Shivaani .
INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) :340-346
[49]   Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape [J].
Jiang, Xianjie ;
Wang, Jie ;
Deng, Xiangying ;
Xiong, Fang ;
Ge, Junshang ;
Xiang, Bo ;
Wu, Xu ;
Ma, Jian ;
Zhou, Ming ;
Li, Xiaoling ;
Li, Yong ;
Li, Guiyuan ;
Xiong, Wei ;
Guo, Can ;
Zeng, Zhaoyang .
MOLECULAR CANCER, 2019, 18 (1)
[50]   CircRBM33 downregulation inhibits hypoxia-induced glycolysis and promotes apoptosis of breast cancer cells via a microRNA-542-3p/HIF-1α axis [J].
Jiang, Yiming ;
Zhang, Meiqi ;
Yu, Danlu ;
Hou, Guoxin ;
Wu, Jingyi ;
Li, Fuming .
CELL DEATH DISCOVERY, 2022, 8 (01)
12345678910